Concomitant Treatment of Malignant Brain Tumours With CBD - A Case Series and Review of the Literature

Anticancer Res. 2019 Oct;39(10):5797-5801. doi: 10.21873/anticanres.13783.


Grade IV glioblastoma multiforme is a deadly disease, with a median survival of around 14 to 16 months. Maximal resection followed by adjuvant radiochemotherapy has been the mainstay of treatment since many years, although survival is only extended by a few months. In recent years, an increasing number of data from in vitro and in vivo research with cannabinoids, particularly with the non-intoxicating cannabidiol (CBD), point to their potential role as tumour-inhibiting agents. Herein, a total of nine consecutive patients with brain tumours are described as case series; all patients received CBD in a daily dose of 400 mg concomitantly to the standard therapeutic procedure of maximal resection followed by radiochemotherapy. By the time of the submission of this article, all but one patient are still alive with a mean survival time of 22.3 months (range=7-47 months). This is longer than what would have been expected.

Keywords: Cannabidiol; brain tumours; cannabinoids; chemoradiation; glioblastoma multiforme.

MeSH terms

  • Adolescent
  • Adult
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality
  • Brain Neoplasms / therapy*
  • Cannabidiol / therapeutic use*
  • Chemoradiotherapy, Adjuvant / methods
  • Child, Preschool
  • Combined Modality Therapy / methods
  • Female
  • Glioblastoma / drug therapy*
  • Glioblastoma / mortality
  • Glioblastoma / therapy*
  • Humans
  • Male
  • Middle Aged
  • Survival Rate


  • Cannabidiol